HEALTH
- Share via
Centocor Stock Gains 68% After Tests: Shares of the biotechnology company surged after it reported early positive test results that could significantly expand the use of its blood clot-busting drug ReoPro. Centocor Inc. said the data show that the drug reduced death and heart attacks in patients undergoing coronary angioplasty procedures to open up blocked arteries in the heart by nearly 70%. Centocor stock closed up $9.75 at $24 on the Nasdaq market, where more than 14 million shares traded.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
